Study Summary
This is a clinical study to evaluate the safety and efficacy of donor-derived CAR-T cells in the treatment of patients with relapsed or refractory acute myeloid leukemia in China.
Want to learn more about this trial?
Request More InfoInterventions
CAR-T cellsDRUG
Drug: IM73 CAR-T Cells Drug: Fludarabine Two days before cell infusion, patient will be treated with fludarabine for 3 days Drug: Cyclophosphamide: Two days before cell infusion, patient will be treated with Cyclophosphamide for 3 days
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Peking University People's Hospital (PKUPH) | Beijing | China |